Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease

Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission

(2015) Konstantinos Papamichael et al.   Clinical Gastroenterology and Hepatology

Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases

(2014) B. Pariente et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

(2014) Filip Baert et al.   Clinical Gastroenterology and Hepatology

Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study

(2014) Armelle Chauvin et al.   DIGESTIVE AND LIVER DISEASE

Stopping Anti-TNF Agents in Patients with Crohnʼs Disease in Remission

(2014) Dario Sorrentino et al.   INFLAMMATORY BOWEL DISEASES

Outcome After Discontinuation of TNFα-blocking Therapy in Patients with Inflammatory Bowel Disease in Deep Remission

(2014) Pauliina Molander et al.   INFLAMMATORY BOWEL DISEASES

Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in Crohnʼs Disease

(2014) Sylvie Rajca et al.   INFLAMMATORY BOWEL DISEASES

Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission

(2014) A.J. Brooks et al.   Journal of Crohns & Colitis

Mucosal Healing Did Not Predict Sustained Clinical Remission in Patients with IBD after Discontinuation of One-Year Infliximab Therapy

(2014) Cong Dai et al.   PLoS One

Optimizing anti-TNF treatments in inflammatory bowel disease

(2013) Shomron Ben-Horin et al.   AUTOIMMUNITY REVIEWS

Is It Possible to Withdraw Biologics From Therapy in Rheumatoid Arthritis?

(2013) Yoshiya Tanaka et al.   CLINICAL THERAPEUTICS

Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis

(2013) A. D. M. Vorselaars et al.   EUROPEAN RESPIRATORY JOURNAL

Targeting TNF-α for the treatment of inflammatory bowel disease

(2013) Thomas Billiet et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Clinical course of patients with Behçet’s uveitis following discontinuation of infliximab therapy

(2013) Tatsushi Kawaguchi et al.   JAPANESE JOURNAL OF OPHTHALMOLOGY

When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel

(2013) Valerie Pittet et al.   Journal of Crohns & Colitis

Serum calprotectin as a biomarker for Crohn's disease

(2013) M.-A. Meuwis et al.   Journal of Crohns & Colitis

Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy

(2013) Klaudia Farkas et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease

(2013) Renathe Rismo et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

The great debate: stopping immunomodulators and biologics in Crohn’s disease patients in remission

(2013) Jana G Hashash et al.   Expert Review of Gastroenterology & Hepatology

Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy

(2012) T. Molnár et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

(2012) Kavinderjit S Nanda et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Can we reduce the dosage of biologics in spondyloarthritis?

(2012) Ignazio Olivieri et al.   AUTOIMMUNITY REVIEWS

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study

(2012) Casper Steenholdt et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Crohn’s disease genotypes of patients in remissionvsrelapses after infliximab discontinuation

(2012) Cathy Lu   WORLD JOURNAL OF GASTROENTEROLOGY

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

(2011) Edouard Louis et al.   GASTROENTEROLOGY

Practical application of anti-TNF therapy for luminal Crohnʼs disease

(2011) Michael A. Kamm et al.   INFLAMMATORY BOWEL DISEASES

Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission

(2011) Kofi Clarke et al.   INFLAMMATORY BOWEL DISEASES

Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort

(2010) A. W. G. Waugh et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Low-Dose Maintenance Therapy With Infliximab Prevents Postsurgical Recurrence of Crohn's Disease

(2010) Dario Sorrentino et al.   Clinical Gastroenterology and Hepatology

The tolerance and efficacy of a postponed retreatment with infliximab in Crohn’s disease primary responders

(2009) D. LAHARIE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease?

(2008) T. Molnár et al.   Journal of Crohns & Colitis